ANIP - ANI Pharmaceuticals' generic drug for anxiety disorder gets FDA approval

ANI Pharmaceuticals (NASDAQ:ANIP) said the U.S. Food and Drug Administration (FDA) approved its generic clorazepate dipotassium tablets used to manage anxiety disorders. The company said the clorazepate dipotassium tablets are a generic version of Tranxene. "The imminent launch and commercialization of Clorazepate Dipotassium Tablets is another example of our ongoing commitment to ensuring that patients in need have access to important therapeutics,” said ANI President and CEO Nikhil Lalwani. ANIP +4.19% to $26.08 premarket June 22

For further details see:

ANI Pharmaceuticals' generic drug for anxiety disorder gets FDA approval